Thursday, October 17, 2019

 


Acasti Pharma Inc
(TSX-V: ACST.VN) Add to Watchlist
$2.820
-0.040 (-1.40%)
as of Oct 16, 2019

Last 2.820
Change -0.040 (-1.40%)
Open 2.860
Prev. Close 2.860
Today's Range
2.750 2.860
52wk Range
0.810 3.880
Volume 35,401
Avg Volume 70,366

Recent Headlines
Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced th  (full story)
ACST: 2.14 (-0.02), ACST.VN: 2.820 (-0.040)
Nearly 80% of randomized patients have completed the studies  (full story)
ACST: 2.14 (-0.02), ACST.VN: 2.820 (-0.040)
Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today annou  (full story)
ACST: 2.14 (-0.02), ACST.VN: 2.820 (-0.040)
Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced th  (full story)
ACST: 2.14 (-0.02), ACST.VN: 2.820 (-0.040)
Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), announc  (full story)
ACST: 2.14 (-0.02), ACST.VN: 2.820 (-0.040)
Performance Comparison
Name Today 3-Month 1-Year
ACST.VN -1.40% -10.76% +84.31%
$TXCX +0.05% +0.96% +5.44%
$TXSC +0.05% +1.50% +6.91%
DJIA -0.08% +3.74% +4.67%
S&P 500 -0.20% +3.74% +6.40%

Key Statistics
Annual EPS -0.870
Dividend & Yield -- (--)
P/E Ratio N/A
Market Capitalization, $K 242,579
Weighted Alpha +107.40
Standard Deviation -0.47
Profit Margin --
Beta -0.468

Growth Rates
YTD +147.37%
1-Year +113.64%
3-Year +61.14%
© 2019 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.